AR074089A1 - Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 - Google Patents
Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2Info
- Publication number
- AR074089A1 AR074089A1 ARP090104282A ARP090104282A AR074089A1 AR 074089 A1 AR074089 A1 AR 074089A1 AR P090104282 A ARP090104282 A AR P090104282A AR P090104282 A ARP090104282 A AR P090104282A AR 074089 A1 AR074089 A1 AR 074089A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- pgd2
- unsubstituted
- heteroalkyl
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 2
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se describen compuestos que son antagonistas de receptores de la PGD2. También, se describen composiciones farmacéuticas que incluyen los compuestos que se describen en la presente, así como los métodos para la utilizacion de dichos antagonistas de ?os receptores de la PGD2, solos o en combinacion con otros compuestos, para el tratamiento de condiciones o enfermedades respiratorias, cardiovasculares y otras condiciones o enfermedades dependientes de la PGD2 o mediadas por la PGD2. Reivindicacion 1: Un compuesto que tiene la estructura de la formula (1), sal aceptable desde el punto de vista farmacéutico o N-oxido del mismo, caracterizado porque cada RA es independientemente H, F, Cl, Br, I, -CN, -NO2, alquilo C1-4, fluoroalquilo C1-4, fluoroalcoxi C1-4, alcoxi C1-4, o heteroalquilo C1-4; R2 es H o alquilo C1-4; R3 es H, alquilo C1-4, fluoroalquilo C1-4 o -L3-X3; -L3- es -alquileno C1-4-; -X3 es H, F, -CN, -CO2R13, -C(=O)N(R13)2, tetrazolilo, u -OH; R12 es alquilo C1-6, haloalquilo C1-6, heteroalquilo C1-6, un fenilo substituido o no substituido, un naftilo substituido o no substituido, un heteroarilo monocíclico substituido o no substituido o un heteroarilo bicíclico substituido o no substituido, caracterizado porque si R12 es substituido entonces R12 es substituido con 1 o 2 R14; cada R14 es independientemente H, F, Cl, Br, I, -CN, -NH2 -OH, -NH(CH3), -N(CH3)2, alquilo C1-4, fluoroalquilo C1-4, alcoxi C1-4, fluoroalcoxi C1-4, o heteroalquilo C1-4; cada R13 es independientemente H, alquilo C1-4, o un fenilo substituido o no substituido; n es 1 o 2; p es 0, 1 o 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11204408P | 2008-11-06 | 2008-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074089A1 true AR074089A1 (es) | 2010-12-22 |
Family
ID=42132183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104282A AR074089A1 (es) | 2008-11-06 | 2009-11-05 | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110301168A1 (es) |
| AR (1) | AR074089A1 (es) |
| GB (1) | GB2465062B (es) |
| TW (1) | TW201022265A (es) |
| UY (1) | UY32225A (es) |
| WO (2) | WO2010054113A2 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061681A2 (en) * | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc | Antagonists of pgd2 receptors |
| WO2009061676A2 (en) * | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
| GB2460597B8 (en) * | 2008-02-01 | 2014-03-12 | Amira Pharmaceuticals Inc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| WO2009099902A1 (en) * | 2008-02-01 | 2009-08-13 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| EP2245022A4 (en) * | 2008-02-25 | 2012-02-22 | Panmira Pharmaceuticals Llc | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| JP2011518130A (ja) * | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト |
| US20110112134A1 (en) * | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| US8501959B2 (en) | 2008-06-24 | 2013-08-06 | Panmira Pharmaceuticals, Llc | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
| CA2768492A1 (en) | 2009-07-31 | 2011-02-03 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| WO2011017201A2 (en) * | 2009-08-05 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Dp2 antagonist and uses thereof |
| US8697869B2 (en) | 2010-03-22 | 2014-04-15 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| SG193902A1 (en) | 2011-04-14 | 2013-11-29 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| UA117780C2 (uk) * | 2014-03-17 | 2018-09-25 | Ідорсія Фармасьютікалз Лтд | Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2 |
| TW201620909A (zh) * | 2014-03-18 | 2016-06-16 | 艾克泰聯製藥有限公司 | 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途 |
| MX379014B (es) * | 2015-09-15 | 2025-03-10 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| CA3075688A1 (en) | 2017-09-13 | 2019-03-21 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| WO2019166635A1 (en) | 2018-03-01 | 2019-09-06 | Universität Basel Vizerektorat Forschung | Dielectric elastomer transducer and corresponding fabrication process |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN111166899A (zh) * | 2020-01-07 | 2020-05-19 | 安徽省双科药业有限公司 | 山梨醇滴眼液湿热灭菌方法 |
| US20240002376A1 (en) * | 2020-08-25 | 2024-01-04 | City Of Hope | Compositions and methods for g-protein-coupled receptor 44 detection |
| CN115466776B (zh) * | 2022-09-26 | 2025-06-27 | 中国医学科学院基础医学研究所 | 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4027278A1 (de) | 1990-08-29 | 1992-03-05 | Bayer Ag | Heterocyclisch substituierte indolsulfonamide |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| JP2002076352A (ja) * | 2000-08-31 | 2002-03-15 | Semiconductor Energy Lab Co Ltd | 表示装置及びその作製方法 |
| US20030096813A1 (en) | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| JP4279561B2 (ja) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体 |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| WO2003097598A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| DE60305724T2 (de) | 2002-10-21 | 2006-11-09 | Warner-Lambert Co. Llc | Tetrahydrochinolin-derivate als crth2 antagonisten |
| EP1558614B1 (en) | 2002-10-30 | 2010-09-01 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
| JP2004182657A (ja) | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Ｈｄｌレベル上昇促進剤 |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| DK1471057T3 (da) | 2003-04-25 | 2006-05-15 | Actimis Pharmaceuticals Inc | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 |
| EP1675826A1 (en) | 2003-10-14 | 2006-07-05 | Oxagen Limited | Compounds having crth2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| BRPI0508540B8 (pt) | 2004-03-11 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| WO2006052798A2 (en) * | 2004-11-08 | 2006-05-18 | Merck & Co., Inc. | Method of treating pathological blushing |
| PL1833791T3 (pl) * | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
| JP4972644B2 (ja) | 2005-08-12 | 2012-07-11 | メルク カナダ インコーポレイテッド | Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 |
| BRPI0616574A2 (pt) | 2005-09-27 | 2009-11-24 | Shionogi & Co | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 |
| WO2007070892A2 (en) * | 2005-12-16 | 2007-06-21 | Ironwood Pharmaceuticals, Inc. | Useful indole compounds |
| GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| GB0611695D0 (en) | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| HRP20120044T1 (hr) * | 2006-08-07 | 2012-02-29 | Actelion Pharmaceuticals Ltd. | Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-octene kiseline |
| WO2008019357A2 (en) * | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| KR20100023046A (ko) | 2007-06-21 | 2010-03-03 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제의 미립자 |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| GB0719521D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| KR101442663B1 (ko) * | 2007-10-10 | 2014-09-22 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Ｃｒｔｈ2 수용체 길항제로서의 헤테로고리 화합물 |
| GB0722203D0 (en) | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| GB0722216D0 (en) | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| AU2009204700B2 (en) | 2008-01-18 | 2013-07-04 | Atopix Therapeutics Limited | Compounds having CRTH2 antagonist activity |
| US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| US8501959B2 (en) | 2008-06-24 | 2013-08-06 | Panmira Pharmaceuticals, Llc | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2010085820A2 (en) | 2009-01-26 | 2010-07-29 | Amira Pharmaceuticals, Inc. | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
| CA2768492A1 (en) | 2009-07-31 | 2011-02-03 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| SG177736A1 (en) | 2009-07-31 | 2012-02-28 | Panmira Pharmaceuticals Llc | Dermal formulations of dp2 receptor antagonists |
-
2009
- 2009-11-03 GB GB0919199A patent/GB2465062B/en not_active Expired - Fee Related
- 2009-11-05 AR ARP090104282A patent/AR074089A1/es not_active Application Discontinuation
- 2009-11-05 WO PCT/US2009/063438 patent/WO2010054113A2/en not_active Ceased
- 2009-11-05 US US13/127,219 patent/US20110301168A1/en not_active Abandoned
- 2009-11-05 WO PCT/US2009/063439 patent/WO2010054114A2/en not_active Ceased
- 2009-11-05 US US12/613,424 patent/US8034826B2/en not_active Expired - Fee Related
- 2009-11-06 TW TW098137816A patent/TW201022265A/zh unknown
- 2009-11-06 UY UY0001032225A patent/UY32225A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010054114A2 (en) | 2010-05-14 |
| WO2010054113A3 (en) | 2010-08-19 |
| US20110301168A1 (en) | 2011-12-08 |
| TW201022265A (en) | 2010-06-16 |
| US20100113503A1 (en) | 2010-05-06 |
| GB2465062A (en) | 2010-05-12 |
| UY32225A (es) | 2010-06-30 |
| GB2465062B (en) | 2011-04-13 |
| GB0919199D0 (en) | 2009-12-16 |
| WO2010054113A2 (en) | 2010-05-14 |
| WO2010054114A3 (en) | 2010-08-19 |
| US8034826B2 (en) | 2011-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 | |
| AR078495A1 (es) | Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico | |
| AR073319A1 (es) | Antagonistas de heteroarilo de receptores de prostaglandina d2 | |
| AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
| AR078497A1 (es) | Isoxazoles como antagonistas de los receptores de acido lisofosfatidico | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR077516A1 (es) | Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2. uso. compuesto. | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| BR112012033075A2 (pt) | composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto. | |
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| ECSP10010439A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| AR092835A1 (es) | Compuestos de d-aminoacido para enfermedades del higado | |
| AR081390A1 (es) | Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra) | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| EP2694060A4 (en) | SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
| AR077969A1 (es) | Derivados de (tio)morfolina comomoduladores de s1p | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| AR077819A1 (es) | Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |